[go: up one dir, main page]

MX2020008181A - Anticuerpo anti-b7-h4, fragmento de union al antigeno y uso farmaceutico del mismo. - Google Patents

Anticuerpo anti-b7-h4, fragmento de union al antigeno y uso farmaceutico del mismo.

Info

Publication number
MX2020008181A
MX2020008181A MX2020008181A MX2020008181A MX2020008181A MX 2020008181 A MX2020008181 A MX 2020008181A MX 2020008181 A MX2020008181 A MX 2020008181A MX 2020008181 A MX2020008181 A MX 2020008181A MX 2020008181 A MX2020008181 A MX 2020008181A
Authority
MX
Mexico
Prior art keywords
antibody
antigen
binding fragment
same
pharmaceutical use
Prior art date
Application number
MX2020008181A
Other languages
English (en)
Inventor
Rudi Bao
Fujun Zhang
Haiqing Hua
Suxia Liu
Ting Wang
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of MX2020008181A publication Critical patent/MX2020008181A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un anticuerpo anti-B7-H4, un fragmento de unión a antígeno del mismo y uso farmacéutico del mismo. Un anticuerpo quimérico y un anticuerpo humanizado que comprende una región CDR delanticuerpo anti-B7-H4, una composición farmacéutica que comprende el anticuerpo anti-B7-H4 y el fragmento de unión al antígeno del mismo, y su uso como medicamento contra el cáncer. Un anticuerpo anti-B7-H4 humanizado y su uso en la preparación de un medicamento para tratar enfermedades o afecciones mediadas por B7-H4.
MX2020008181A 2018-02-11 2019-02-01 Anticuerpo anti-b7-h4, fragmento de union al antigeno y uso farmaceutico del mismo. MX2020008181A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810142118 2018-02-11
PCT/CN2019/074397 WO2019154315A1 (zh) 2018-02-11 2019-02-01 抗b7-h4抗体、其抗原结合片段及其医药用途

Publications (1)

Publication Number Publication Date
MX2020008181A true MX2020008181A (es) 2020-09-18

Family

ID=67548182

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008181A MX2020008181A (es) 2018-02-11 2019-02-01 Anticuerpo anti-b7-h4, fragmento de union al antigeno y uso farmaceutico del mismo.

Country Status (12)

Country Link
US (1) US11472882B2 (es)
EP (1) EP3753951A4 (es)
JP (2) JP7393337B2 (es)
KR (1) KR20200119846A (es)
CN (2) CN110366560B (es)
AU (1) AU2019218319B2 (es)
BR (1) BR112020015736A2 (es)
CA (1) CA3089246A1 (es)
MX (1) MX2020008181A (es)
TW (1) TWI823895B (es)
WO (1) WO2019154315A1 (es)
ZA (1) ZA202004701B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3753951A4 (en) * 2018-02-11 2022-03-16 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ANTI-B7-H4 ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
WO2020244657A1 (zh) * 2019-06-06 2020-12-10 上海翰森生物医药科技有限公司 抗b7-h4抗体-药物偶联物及其医药用途
CN115298220B (zh) * 2020-03-24 2024-12-20 上海翰森生物医药科技有限公司 抗体-药物偶联物及其医药用途
TW202144425A (zh) * 2020-04-17 2021-12-01 大陸商上海翰森生物醫藥科技有限公司 特異性抗原結合分子，其製備方法及醫藥用途
KR20230026489A (ko) 2020-06-24 2023-02-24 프로테나 바이오사이언시즈 리미티드 소르틸린을 인지하는 항체
EP4387997A4 (en) * 2020-08-18 2025-07-30 Abl Bio Inc BISPECIFIC ANTI-B7-H4/ANTI-4-1BB ANTIBODIES AND THEIR USES
WO2022147532A1 (en) 2021-01-04 2022-07-07 Mersana Therapeutics, Inc. B7h4-targeted antibody-drug conjugates and methods of use thereof
WO2022200525A1 (en) 2021-03-26 2022-09-29 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
CN117616050A (zh) 2021-06-09 2024-02-27 先天制药公司 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
WO2023283345A1 (en) * 2021-07-07 2023-01-12 Incyte Corporation Anti-b7-h4 antibodies and uses thereof
TW202346320A (zh) * 2021-12-01 2023-12-01 美商凱德蒙有限責任公司 Ｂ７－ｈ４抗體和抗ｂ７－ｈ４抗體／ｉｌ－１５融合蛋白
AR128076A1 (es) * 2021-12-23 2024-03-20 Prothena Biosciences Ltd Anticuerpos que reconocen la sortilina
WO2023186015A1 (zh) * 2022-03-30 2023-10-05 映恩生物制药（苏州）有限公司 B7h4抗体药物偶联物及其用途
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor
CN121127268A (zh) * 2023-04-12 2025-12-12 上海翰森生物医药科技有限公司 抗体药物偶联物在制备预防和/或治疗癌症的药物中的用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858710B2 (en) * 1998-12-17 2005-02-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030091580A1 (en) * 2001-06-18 2003-05-15 Mitcham Jennifer L. Compositions and methods for the therapy and diagnosis of ovarian cancer
US8759490B2 (en) * 2005-03-24 2014-06-24 Millennium Pharamaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
EP2384767B1 (en) * 2005-03-24 2016-03-09 Millennium Pharmaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
CN101951959A (zh) * 2007-11-30 2011-01-19 百时美施贵宝公司 抗b7h4单克隆抗体-药物缀合物和使用方法
PL2603523T3 (pl) * 2010-08-12 2016-07-29 Lilly Co Eli Przeciwciała przeciwko peptydowi amyloidu beta N3pGlu i ich zastosowania
EP2756094B1 (en) * 2011-08-15 2017-12-27 Medlmmune, LLC Anti-b7-h4 antibodies and their uses
WO2013157105A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
CA2894879A1 (en) * 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
US9562099B2 (en) * 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
WO2014159835A1 (en) * 2013-03-14 2014-10-02 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
CN103981150B (zh) 2014-03-28 2016-06-01 苏州大学 抗人b7-h4单克隆抗体及其制备和应用
WO2016040724A1 (en) * 2014-09-12 2016-03-17 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
US20180118831A1 (en) * 2015-03-27 2018-05-03 University Of Southern California Car t-cells for the treatment of b7-h4 expressing solid tumors
KR102346988B1 (ko) * 2016-07-26 2022-01-03 시즈오카켄 항 b7-h4 항체
CN107299085B (zh) * 2017-05-26 2020-09-29 广东医科大学 分泌抗人b7-h4胞外单克隆抗体杂交瘤细胞株和抗人b7-h4单克隆抗体及其应用
EP3753951A4 (en) * 2018-02-11 2022-03-16 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ANTI-B7-H4 ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
MA52416A (fr) * 2018-03-02 2021-04-21 Five Prime Therapeutics Inc Anticorps b7-h4 et leurs procédés d'utilisation
KR102227515B1 (ko) 2018-12-18 2021-03-12 주식회사 포스코 제올라이트 및 그 제조방법

Also Published As

Publication number Publication date
ZA202004701B (en) 2023-12-20
JP2024026132A (ja) 2024-02-28
TWI823895B (zh) 2023-12-01
JP2021513331A (ja) 2021-05-27
BR112020015736A2 (pt) 2020-12-08
US20210032347A1 (en) 2021-02-04
CA3089246A1 (en) 2019-08-15
WO2019154315A1 (zh) 2019-08-15
CN110366560B (zh) 2023-07-28
AU2019218319A1 (en) 2020-08-13
CN110366560A (zh) 2019-10-22
EP3753951A1 (en) 2020-12-23
AU2019218319B2 (en) 2025-11-13
RU2020124155A (ru) 2022-03-11
KR20200119846A (ko) 2020-10-20
EP3753951A4 (en) 2022-03-16
JP7393337B2 (ja) 2023-12-06
TW201934581A (zh) 2019-09-01
US11472882B2 (en) 2022-10-18
CN116693686A (zh) 2023-09-05

Similar Documents

Publication Publication Date Title
MX2020008181A (es) Anticuerpo anti-b7-h4, fragmento de union al antigeno y uso farmaceutico del mismo.
ECSP16060104A (es) Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este
MX2021009041A (es) Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
MX2021005396A (es) Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo.
MX2024007358A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
BR112021019135A2 (pt) Anticorpo anticlaudina 18.2 e aplicação do mesmo
MX2018010733A (es) Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
MX2022004082A (es) Anticuerpos biespecificos contra cd3 y cd20.
GEP20217252B (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
EP4406610A3 (en) Treatment of cancer using anti-cd19 chimeric antigen receptor
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2017012615A (es) Anticuerpo anti-notch4 humano.
BR112016027881A2 (pt) antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
MX2019015914A (es) Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MY209791A (en) Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
MX2021003168A (es) Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico.
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
MX2020003034A (es) Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica.
MX2018007925A (es) Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
ZA202201946B (en) Anti-bcma antibody, antigen-binding fragment thereof and medical use thereof